Across TCGA pan-cancer cohorts, ATP6V0A2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP6V0A2 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATP6V0A2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP6V0A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SKCM, and COAD are the cancer types where ATP6V0A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.619	.007	10	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
COAD	OS	Median	II,III,IV	0.191	0.601	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ATP6V0A2 tumor-vs-normal RNA expression · all ATP6V0A2 data types